EP1887013A1 - A process for preparing didanosine - Google Patents
A process for preparing didanosine Download PDFInfo
- Publication number
- EP1887013A1 EP1887013A1 EP05772872A EP05772872A EP1887013A1 EP 1887013 A1 EP1887013 A1 EP 1887013A1 EP 05772872 A EP05772872 A EP 05772872A EP 05772872 A EP05772872 A EP 05772872A EP 1887013 A1 EP1887013 A1 EP 1887013A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- water
- mixture
- compound
- salt
- dideoxyinosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 title claims abstract description 28
- 229960002656 didanosine Drugs 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000007062 hydrolysis Effects 0.000 claims abstract description 7
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract description 6
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims abstract description 6
- 125000006239 protecting group Chemical group 0.000 claims abstract description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- TYQPBHYPIRLWKU-NKWVEPMBSA-N 9-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-3h-purin-6-one Chemical compound C1=C[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 TYQPBHYPIRLWKU-NKWVEPMBSA-N 0.000 claims description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- -1 e.g. Chemical class 0.000 claims description 6
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 5
- 238000005984 hydrogenation reaction Methods 0.000 claims description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 4
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000007868 Raney catalyst Substances 0.000 claims description 4
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 229910001413 alkali metal ion Inorganic materials 0.000 claims description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 150000001768 cations Chemical group 0.000 claims description 3
- 150000007529 inorganic bases Chemical class 0.000 claims description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 claims description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- QSKDAQIJIZLBFT-UHFFFAOYSA-N 2-acetyloxy-2,5,5-trimethyl-1,3-dioxolane-4-carboxylic acid Chemical compound CC(=O)OC1(OC(C(O1)(C)C)C(=O)O)C QSKDAQIJIZLBFT-UHFFFAOYSA-N 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 238000006386 neutralization reaction Methods 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 239000000243 solution Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- CBSZEQIVWRWHSA-NZGZCVLKSA-N 9-[(2r,5s)-5-[(2,4,4-trimethyl-5-oxo-1,3-dioxolan-2-yl)oxymethyl]-2,5-dihydrofuran-2-yl]-3h-purin-6-one Chemical compound C([C@@H]1C=C[C@@H](O1)N1C2=C(C(N=CN2)=O)N=C1)OC1(C)OC(=O)C(C)(C)O1 CBSZEQIVWRWHSA-NZGZCVLKSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 150000002892 organic cations Chemical class 0.000 description 2
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention relates to a method for the preparation of didanosine.
- Didanosine is an antiviral drug used to treat human immunodeficiency virus (HIV) infection. It was developed at the National Cancer Institute ( US Pat No.: 4,861,759 ). The chemical name for didanosine is 2',3'-dideoxyinosine (DDI). Didanosine is one of the most important anti-HIV drugs. There are two main synthetic routes to didanosine: 1) catalytic hydrogenation of compound II (below) and removal of protecting group; and 2) removal of protecting group (R) in position 5' from compound II to obtaib 2',3'-didehydro-2',3'-dideoxyinosine ("D4l”), followed by hydrogenated to obtain DDI.
- D4l obtaib 2',3'-didehydro-2',3'-dideoxyinosine
- the problem to be solved is to overcome the shortcomings of the methods mentioned above, and to provide a new method for preparing 2',3'-dideoxyinosine (DDI) of a high purity.
- the invention provides a new method to prepare didanosine of formula I.
- This new method comprises (a) removing the protecting group in position 5' of the compound II by hydrolysis under basic reaction conditions, and simultaneously enolizing the carbonyl group of the purine ring to yield the stable salt III, i.e. the salt of 2',3'-didehydro-2',3'- dideoxyinosine (X-D4l); (b) producing the salt of 2',3'-dideoxyinosine(X-DDI) through catalytic hydrogenation of X-D4l; and (c) neutralizing X-DDI with acid to obtain compound I, i.e., didanosine.
- X is a cation, including an organic cation, such as, e.g., an alkali metal ion, an ammonium ion, or a quaternary ammonium cation; preferably, Na + , K + , NH 4 + or CH 3 NH 3 + , and more preferably Na + ;
- Y is a corresponding anion;
- R is acyl, acetoxy, alkyl, or silyl, such as, e.g., acetyloxy, 2,5,5-trimethyl-1,3-dioxolane -4-carboxylate, or tert-butyldimethylsilyl.
- compound IV is obtained by catalytically hydrogenating compound III or its hydrate in a purified form or as crude solution from the previous step.
- the pH in the range of between 8.5 and 9.5 is preferable for hydrogenation.
- the catalyst used in hydrogenation is Raney nickel or palladium carbon, and it can be re-used. Then, compound IV is neutralized with acid to yield didanosine of high purity.
- a suitable solvent should be used and the pH should be maintained at above 8.
- the solvent can be water, ammonia water, lye, alcohol, alcohol water mixtures, ketone water mixtures, or nitrile water mixtures, etc., such as, e.g., methanol, a mixture of methanol and water, a mixture of ethanol and water, a mixture of isopropanol and water, a mixture of acetonitrile and water, a mixture of acetone and water, ammonia water, or a mixture of methylamine and water, etc.
- the acid used for neutralization is an inorganic acid or an organic acid, such as, e.g., hydrochloric acid, acetic acid, etc, and preferably acetic acid.
- the base used in the hydrolysis of compound II to compound III can be an inorganic base, an organic base, or a mixture thereof, as long as the pH of the solution is maintained above 8.5, and preferably the base is a solution of potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, or methylamine.
- the other object of the invention is to provide a new key intermediate compound III (X-D4l ⁇ nH 2 O) useful in the synthesis of didanosine.
- Said compound is a water soluble, stable salt of 2',3'-didehydro-2',3'- dideoxyinosine, the structural formula of which is as follows: wherein X is a cation, such as, e.g., Na + , K + , Mg ++ , Ca ++ , or NH 4 + , and n is between 0 and 3.
- These salts include salts obtained with organic cations, alkali, alkali metal ions, ammonium ions, or quaternary ammonium cations, and sodium salts are preferable.
- An alkali metal salt can be obtained by the reaction of an alkali metal with compound II. When the pH of the solution is above 8, the product is very stable. In solid form, the product is a hydrate and the number of water molecules is between
- Compound II is hydrolyzed in a solution with the pH above 8.5 to yield X-D4l. After adding organic solvent, compound III (X-D4l ⁇ nH 2 O) crystallizes out.
- the base used in hydrolysis is an inorganic base, an organic base, or a mixture thereof; and preferably potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, or methylamine.
- the organic solvent should be water-soluble, e.g., an alcoholic solvent, a ketonic solvent, a nitrilic solvent, etc., such as, e.g., isopropanol, acetone, acetonitrile, or tetrahydrofuran.
- the method presented herein produces didanosine with high purity, high yield, high quality, and low cost.
- Fig.1 , 2 , and 3 illustrate NMR spectra of the product obtained in Example 3.
- NaOH can be replaced by KOH or strong organic base to obtain a corresponding salt of D4l.
- the filter cake was washed with 100 mL of methanol and dried at a temperature of between 55°C and 60°C. About 60 g of DDI was obtained. If needed, a high purity product can be obtained by recrystallization from methanol.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
This invention provides a method for preparing didanosine. The method comprises removing a protecting group in position 5' of compound II by hydrolysis under basic reaction conditions, and simultaneously enolizing of the carbonyl group of the purine ring to obtain a stable salt, and then producing the salt of 2',3-dideoxyinosine through catalytic hydrogenation, which salt is finally converted with acid to yield the finished product.
Description
- Field of the Invention
- The invention relates to a method for the preparation of didanosine.
- Background of the Invention
- Didanosine is an antiviral drug used to treat human immunodeficiency virus (HIV) infection. It was developed at the National Cancer Institute (
US Pat No.: 4,861,759 ). The chemical name for didanosine is 2',3'-dideoxyinosine (DDI). Didanosine is one of the most important anti-HIV drugs. There are two main synthetic routes to didanosine: 1) catalytic hydrogenation of compound II (below) and removal of protecting group; and 2) removal of protecting group (R) in position 5' from compound II to obtaib 2',3'-didehydro-2',3'-dideoxyinosine ("D4l"), followed by hydrogenated to obtain DDI. - The two methods have the disadvantages of low yield and high cost. However, HIV-infected patients generally require inexpensive treatment, which limits the application of didanosine.
- Description of the invention:
- The problem to be solved is to overcome the shortcomings of the methods mentioned above, and to provide a new method for preparing 2',3'-dideoxyinosine (DDI) of a high purity.
- Thus, the invention provides a new method to prepare didanosine of formula I.
- This new method comprises (a) removing the protecting group in position 5' of the compound II by hydrolysis under basic reaction conditions, and simultaneously enolizing the carbonyl group of the purine ring to yield the stable salt III, i.e. the salt of 2',3'-didehydro-2',3'- dideoxyinosine (X-D4l); (b) producing the salt of 2',3'-dideoxyinosine(X-DDI) through catalytic hydrogenation of X-D4l; and (c) neutralizing X-DDI with acid to obtain compound I, i.e., didanosine.
- The method is illustrated as follows:
wherein X is a cation, including an organic cation, such as, e.g., an alkali metal ion, an ammonium ion, or a quaternary ammonium cation; preferably, Na+, K+, NH4 + or CH3NH3 +, and more preferably Na+; Y is a corresponding anion; R is acyl, acetoxy, alkyl, or silyl, such as, e.g., acetyloxy, 2,5,5-trimethyl-1,3-dioxolane -4-carboxylate, or tert-butyldimethylsilyl. - When pH value is maintained above 8, compound IV is obtained by catalytically hydrogenating compound III or its hydrate in a purified form or as crude solution from the previous step. The pH in the range of between 8.5 and 9.5 is preferable for hydrogenation. The catalyst used in hydrogenation is Raney nickel or palladium carbon, and it can be re-used. Then, compound IV is neutralized with acid to yield didanosine of high purity.
- When compound III is hydrogenated after purification, a suitable solvent should be used and the pH should be maintained at above 8. The solvent can be water, ammonia water, lye, alcohol, alcohol water mixtures, ketone water mixtures, or nitrile water mixtures, etc., such as, e.g., methanol, a mixture of methanol and water, a mixture of ethanol and water, a mixture of isopropanol and water, a mixture of acetonitrile and water, a mixture of acetone and water, ammonia water, or a mixture of methylamine and water, etc.
- The acid used for neutralization is an inorganic acid or an organic acid, such as, e.g., hydrochloric acid, acetic acid, etc, and preferably acetic acid.
- The base used in the hydrolysis of compound II to compound III can be an inorganic base, an organic base, or a mixture thereof, as long as the pH of the solution is maintained above 8.5, and preferably the base is a solution of potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, or methylamine.
- The other object of the invention is to provide a new key intermediate compound III (X-D4l·nH2O) useful in the synthesis of didanosine. Said compound is a water soluble, stable salt of 2',3'-didehydro-2',3'- dideoxyinosine, the structural formula of which is as follows:
wherein X is a cation, such as, e.g., Na+, K+, Mg++, Ca++, or NH4 +, and n is between 0 and 3. These salts include salts obtained with organic cations, alkali, alkali metal ions, ammonium ions, or quaternary ammonium cations, and sodium salts are preferable. An alkali metal salt can be obtained by the reaction of an alkali metal with compound II. When the pH of the solution is above 8, the product is very stable. In solid form, the product is a hydrate and the number of water molecules is between 0.5 and 3. - Compound II is hydrolyzed in a solution with the pH above 8.5 to yield X-D4l. After adding organic solvent, compound III (X-D4l·nH2O) crystallizes out. The base used in hydrolysis is an inorganic base, an organic base, or a mixture thereof; and preferably potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, or methylamine. The organic solvent should be water-soluble, e.g., an alcoholic solvent, a ketonic solvent, a nitrilic solvent, etc., such as, e.g., isopropanol, acetone, acetonitrile, or tetrahydrofuran.
- The method presented herein produces didanosine with high purity, high yield, high quality, and low cost.
- The following examples are intended to show how to practice of invention and are not intended to restrict the scope of thereof.
-
Fig.1 ,2 , and3 illustrate NMR spectra of the product obtained in Example 3. - Example 1
- Preparation of DDI from 5'-acetoxy-D4l
- 20 g of 5'-acetoxy-D4l was dissolved in 200 mL of acetonitrile. The solution was cooled to 5°C. Aqueous NaOH was added dropwise to the reaction mixture while stirring and the pH of the solution was maintained above 8.5. The completion of the protecting group removal was followed by TLC. After deprotection, 70 g of Raney nickel was added and the intermediate was hydrogenated with hydrogen gas at room temperature and normal pressure. The completion of hydrogenation was determined by HPLC. The solution was condensed under reduced pressure, and then neutralized with acetic acid. The crystalline product was filtered and dried. About 14 g of a solid was obtained. The dried DDI was recrystallized from methanol to obtain high purity DDI.
- Example 2
- Preparation of DDI from 2',3'-Didehydro-5'-O-(2,5,5-trimethyl-1,3-dioxolan-4-on-2-yl)-2',3'-dideoxyinosine
- 20 g of 2',3'-Didehydro-5'-O-(2,5,5-trimethyl-1,3-dioxolan-4-on-2-yl)-2',3'-dideoxyinosine was dissolved in 200 mL of acetonitrile. The solution was cooled to 5°C. Aqueous NaOH was slowly added dropwise into the reaction mixture while stirring. The pH of the solution was maintained at above 8.5. The completion of deprotection was followed by TLC. After completion, 50 g of Raney Nickel was added and the intermediate was hydrogenated with hydrogen gas at room temperature and normal pressure. The completion of hydrogenation was followed by HPLC. The solution was condensed under reduced pressure, and then neutralized with acetic acid. The crystallized product was filtered and dried. About 9 g of solid was obtained. The dried DDI was recrystallized with methanol to obtain high purity DDI.
- Example 3
-
- 45 mL of 1 N NaOH solution was cooled down to below 10°C. Then 10 g of D4l was added, and the reaction mixture was stirred for 0.5 hours while maintaining the temperature at 10-15°C. The pH of the solution was maintained at between 9.5 and 11. Then, 600 mL of isopropanol was added slowly, and stirred for 2 hours at room temperature until the product crystallized. The mixture was filtered and the crystals were washed with 100 mL of isopropanol, and then dried in vacuum for 24 hours at a temperature of below 50°C. As a result, about 11 g of Na-D4l·2H2O was obtained.
- Identification tests:
- (1) NMR: See
Figs.1-3 . - (2) Water (Karl Fischer titration): theoretical value is 12.3% and the test result was 12.4%.
- In the above methods, NaOH can be replaced by KOH or strong organic base to obtain a corresponding salt of D4l.
- Example 4
- Preparation of DDI from purified X-D4l·nH2O
- 100 g of Na-D4l·2H2O was dissolved in 1000 mL of methanol. The reaction vessel was flushed with nitrogen. 500 g of activated Raney nickel was added. The reaction mixture was placed under an atmosphere of hydrogen gas for 10 hours under normal pressure. The completion of the reaction was followed by HPLC. At the completion of the reaction, the solution was filtered and condensed under reduced pressure to a volume of 100 mL. The condensed solution was then cooled to room temperature, and acetic acid was added dropwise while stirring. The pH was adjusted to between 6.5 and 7 and a white solid crystallized out. The mixture was stirred for 1 hour at room temperature and filtered. The filter cake was washed with 100 mL of methanol and dried at a temperature of between 55°C and 60°C. About 60 g of DDI was obtained. If needed, a high purity product can be obtained by recrystallization from methanol.
Claims (8)
- A method of preparing compound I, comprising:(a) removing the protecting group in position 5' in compound II by hydrolysis under basic condition, and simultaneously enolizing of the carbonyl group of the purine ring to yield a stable salt of of 2',3'-didehydro-2',3'- dideoxyinosine having formula III,(b) producing the salt of 2',3'-dideoxyinosine of formula IV via catalytic hydrogenation, andwherein R is acyl, alkyl or silyl; X is a cation; Y is a corresponding anion; and n is between 0 and 3.
- The method of claim 1, wherein X is an alkali metal ion, an ammonium ion, a quaternary ammonium cation, such as, Na+, K+, NH4 + or CH3NH3 +.
- The method of claim 1, wherein the solvent used for the preparation of compound IV from compound III through catalytic hydrogenation is selected from water, ammonia water, lye, an alcohol, a mixture of alcohol and water, a mixture of a ketone and water, a mixture of a nitrile and water, etc., e.g., methanol, a mixture of methanol and water, a mixture of ethanol and water, a mixture of isopropanol and water, a mixture of acetonitrile and water, a mixture of acetone and water, ammonia water or a mixture of methylamine and water; the catalyst used in the hydrogenation is Raney nickel or palladium on carbon, and the pH during the catalytic hydrogenation is maintained at between 8 and 14.
- The method of claim 1, wherein the acid used for the preparation of compound I from compound IV through neutralization is an inorganic acid or an organic acid, such as, e.g., hydrochloric acid or acetic acid.
- The method of claim 1, wherein an intermediate in the synthesis of the compound of formula I is the salt of 2',3'-didehydro-2',3'- dideoxyinosine, which has the structure of formula III, as follows:
X is an alkali metal ion, an ammonium ion, or a quaternary ammonium cation, such as, Na+, K+, NH4 + or CH3NH3 +, and n is between 0.5- and 3. - The method of claim 5, wherein said salt of 2',3'-didehydro-2',3'-dideoxyinosine of formula III is obtained by hydrolysis of compound II in a solution having a pH of between 8.5 and 14 or a pH greater than 8.5, followed by crystallization from an organic solvent; and the structural formula of compound II is as follows:
R is an acyl, an acetoxy, an alkyl or a silyl, such as acetyloxy, 2,5,5-trimethyl-1,3-dioxolane -4-carboxylate, or tert-butyldimethylsilyl. - The method of claims 1 or 4, wherein the new compound of formula III or its hydrate can be used in subsequent steps after purification or without purification in a crude form.
- The method of claim 5, wherein the base used in the hydrolysis for the preparation of salt of 2',3'-didehydro-2',3'- dideoxyinosine is an inorganic base, an organic base, or a mixture thereof, such as, e.g., potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, or methylamine, or a mixture thereof; said organic solvent is an alcoholic solvent, a ketonic solvent, or a nitrilic solvent, such as isopropanol, acetone, acetonitrile, or tetrahydrofuran.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100262912A CN100537588C (en) | 2005-05-30 | 2005-05-30 | A kind of synthetic method of didanosine |
| PCT/CN2005/001059 WO2006128328A1 (en) | 2005-05-30 | 2005-07-18 | A process for preparing didanosine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1887013A1 true EP1887013A1 (en) | 2008-02-13 |
Family
ID=37481209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP05772872A Withdrawn EP1887013A1 (en) | 2005-05-30 | 2005-07-18 | A process for preparing didanosine |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1887013A1 (en) |
| CN (1) | CN100537588C (en) |
| WO (1) | WO2006128328A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7750153B2 (en) * | 2005-07-05 | 2010-07-06 | Hetero Drugs Limited | Process for the preparation of didanosine using novel intermediates |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104211746B (en) * | 2014-09-11 | 2016-08-31 | 天方药业有限公司 | A kind of synthetic method of didanosine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455339A (en) * | 1986-05-01 | 1995-10-03 | University Of Georgia Research Foundation, Inc. | Method for the preparation of 2',3'-dideoxy and 2',3'-dideoxydide-hydro nucleosides |
-
2005
- 2005-05-30 CN CNB2005100262912A patent/CN100537588C/en not_active Expired - Fee Related
- 2005-07-18 EP EP05772872A patent/EP1887013A1/en not_active Withdrawn
- 2005-07-18 WO PCT/CN2005/001059 patent/WO2006128328A1/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2006128328A1 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7750153B2 (en) * | 2005-07-05 | 2010-07-06 | Hetero Drugs Limited | Process for the preparation of didanosine using novel intermediates |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006128328A1 (en) | 2006-12-07 |
| CN1872868A (en) | 2006-12-06 |
| CN100537588C (en) | 2009-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1239639A (en) | Epimeric azahomoerythromycin a derivative and intermediates therefor | |
| PT102006B (en) | NEW AZITROMYCIN PREPARATION PROCESS | |
| HU199864B (en) | Process for production of derivatives of macrolide | |
| WO2013008247A1 (en) | Process for preparation of (dl) -norepinephrine acid addition salt, a key intermediate of (r) - (-) - norepinephrine | |
| JPS6241502B2 (en) | ||
| EP0024210B1 (en) | Process for the production of optically active threo-3-(3,4-dihydroxyphenyl) serine, and product thus produced | |
| IE911536A1 (en) | Process for the preparation of¹1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives¹thereof | |
| EP1887013A1 (en) | A process for preparing didanosine | |
| HU221793B1 (en) | Process for the preparation of ropivacaine hydrochloride monohydrate | |
| US7696356B2 (en) | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom | |
| DK170331B1 (en) | Process for the preparation of rimantadine | |
| US3595853A (en) | Ribofuranosyl cytosine and arabinofuranosyl cytosine derivatives | |
| EP1709057B1 (en) | Synthesis of spongosine | |
| US2384105A (en) | Ribitylaminobenzenes and process for the manufacture thereof | |
| CN1035005C (en) | A new method for preparing 6-(3-dimethylaminopropionyl)forskolin | |
| CN101155820A (en) | Preparation method of 6,7,8-trihydroxy-1-hydroxymethyl-3-oxo-2-oxa-4-azabicyclo[3.3.1]nonane | |
| RU2144924C1 (en) | Method of preparing azitromicyn and methods for production of intermediates | |
| EP3031800B1 (en) | Process for the preparation of high purity miglustat | |
| CN113549072B (en) | A preparation method of tofacitinib impurity I | |
| JP5192807B2 (en) | Stable crystals of protected pseudouridine | |
| US20080293938A1 (en) | Novel Process for the Preparation of Didanosine Using Novel Intermediates | |
| WO2007064663A2 (en) | Process for the preparation of 1-(aminomethyl)cyclohexaneacetic acid | |
| JPH09249681A (en) | 6-0-(2-acetamidoethylphosphonyl)-d-mannopyranoside derivative and its production | |
| KR20090010546A (en) | Method for preparing gabapentin and intermediates | |
| JPS633877B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20071027 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20120201 |